Skip to main content
Top
Published in: Annals of Surgical Oncology 8/2017

Open Access 01-08-2017 | Colorectal Cancer

Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases

Authors: Lars Thomas Seeberg, MD, Cathrine Brunborg, MSc, Anne Waage, MD, PhD, Harald Hugenschmidt, MD, Anne Renolen, MSc, Ingunn Stav, MSc, Bjørn A. Bjørnbeth, MD, PhD, Elin Borgen, MD, PhD, Bjørn Naume, MD, PhD, Kristoffer W. Brudvik, MD, PhD, Gro Wiedswang, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2017

Login to get access

Abstract

Objective

The aim of this study was to analyse the survival impact of primary tumor nodal status (N0/N+) in patients with resectable colorectal liver metastases (CLM), and to determine the value of circulating and disseminated tumor cells (CTCs/DTCs) in this setting.

Methods

In this prospective study of patients undergoing resection of CLM from 2008 to 2011, peripheral blood was analyzed for CTCs using the CellSearch System®, and bone marrow was sampled for DTC analyses just prior to hepatic resection. The presence of one or more tumor cells was scored as CTC/DTC-positive. Following resection of the primary tumor, the lymph nodes (LNs) were examined by routine histopathological examination.

Results

A total of 140 patients were included in this study; 38 patients (27.1%) were negative at the primary colorectal LN examination (N0). CTCs were detected in 12.1% of all patients; 5.3% of patients in the N0 group and 14.7% of patients in the LN-positive (N+) group (p = 0.156), with the LN-positive group (N+) consisting of both N1 and N2 patients. There was a significant difference in recurrence-free survival (RFS) when analysing the N0 group versus the N+ group (p = 0.007) and CTC-positive versus CTC-negative patients (p = 0.029). In multivariate analysis, CTC positivity was also significantly associated with impaired overall survival (OS) [p = 0.05], whereas DTC positivity was not associated with survival.

Conclusion

In this cohort of resectable CLM patients, 27% had primary N0 colorectal cancer. Assessment of CTC in addition to nodal status may contribute to improved classification of patients into high- and low-risk groups, which has the potential to guide and improve treatment strategies.
Appendix
Available only for authorised users
Literature
2.
go back to reference Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–77.CrossRefPubMedPubMedCentral Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27:872–77.CrossRefPubMedPubMedCentral
3.
go back to reference Karsa LV, Lignini TA, Patnick J, et al. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010;24:381–96.CrossRefPubMed Karsa LV, Lignini TA, Patnick J, et al. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010;24:381–96.CrossRefPubMed
4.
go back to reference Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–74.CrossRefPubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–74.CrossRefPubMed
5.
go back to reference Rees M, Tekkis PP, Welsh FKS, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:125–35.CrossRefPubMed Rees M, Tekkis PP, Welsh FKS, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:125–35.CrossRefPubMed
6.
go back to reference Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230(3): 309–318; discussion 318–21.CrossRefPubMedPubMedCentral Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg. 1999;230(3): 309–318; discussion 318–21.CrossRefPubMedPubMedCentral
7.
go back to reference Mala T, Bøhler G, Mathisen Ø, et al. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26:1348–53.CrossRefPubMed Mala T, Bøhler G, Mathisen Ø, et al. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26:1348–53.CrossRefPubMed
8.
go back to reference Nordlinger B, Peschaud F, Malafosse R. Resection of liver metastases from colorectal cancer-how can we improve results? Colorectal Dis. 2003;5:515–17.CrossRefPubMed Nordlinger B, Peschaud F, Malafosse R. Resection of liver metastases from colorectal cancer-how can we improve results? Colorectal Dis. 2003;5:515–17.CrossRefPubMed
9.
go back to reference Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57; discussion 657–8.CrossRefPubMedPubMedCentral Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57; discussion 657–8.CrossRefPubMedPubMedCentral
10.
go back to reference Veen T, Nedrebø BS, Stormark K, et al. Qualitative and quantitative issues of lymph nodes as prognostic factor in colon cancer. Dig Surg. 2013;30:1–11.CrossRefPubMed Veen T, Nedrebø BS, Stormark K, et al. Qualitative and quantitative issues of lymph nodes as prognostic factor in colon cancer. Dig Surg. 2013;30:1–11.CrossRefPubMed
11.
go back to reference Veen T, Stormark K, Nedrebø BS, et al. Long-term follow-up and survivorship after completing systematic surveillance in stage I-III colorectal cancer: who is still at risk? J Gastrointest Cancer. 2015;46(3):259–66.CrossRefPubMedPubMedCentral Veen T, Stormark K, Nedrebø BS, et al. Long-term follow-up and survivorship after completing systematic surveillance in stage I-III colorectal cancer: who is still at risk? J Gastrointest Cancer. 2015;46(3):259–66.CrossRefPubMedPubMedCentral
12.
go back to reference Stoecklein NH, Klein CA Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126:589–98.CrossRefPubMed Stoecklein NH, Klein CA Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126:589–98.CrossRefPubMed
13.
14.
go back to reference Bork U, Grützmann R, Rahbari NN, et al. Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 2014;20:10296–304.CrossRefPubMedPubMedCentral Bork U, Grützmann R, Rahbari NN, et al. Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 2014;20:10296–304.CrossRefPubMedPubMedCentral
15.
go back to reference Seeberg LT, Waage A, Brunborg C, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg. 2015;261(1):164–71.CrossRefPubMed Seeberg LT, Waage A, Brunborg C, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg. 2015;261(1):164–71.CrossRefPubMed
16.
go back to reference Torino F, Bonmassar E, Bonmassar L, et al. Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev. 2013;39(7):759–72.CrossRefPubMed Torino F, Bonmassar E, Bonmassar L, et al. Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev. 2013;39(7):759–72.CrossRefPubMed
17.
go back to reference Groot Koerkamp B, Rahbari NN, Büchler MW, et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65.CrossRefPubMed Groot Koerkamp B, Rahbari NN, Büchler MW, et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65.CrossRefPubMed
18.
19.
go back to reference Cancer in Norway 2013. Cancer Registry of Norway; 2015. Cancer in Norway 2013. Cancer Registry of Norway; 2015.
20.
go back to reference Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920–28.CrossRefPubMed Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920–28.CrossRefPubMed
21.
go back to reference Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.CrossRefPubMed Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.CrossRefPubMed
22.
go back to reference Wiedswang G, Borgen E, Kåresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21:3469–3478.CrossRefPubMed Wiedswang G, Borgen E, Kåresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21:3469–3478.CrossRefPubMed
23.
go back to reference Haugland HK, Casati B, Dørum LM, et al. Template reporting matters: a nationwide study on histopathology reporting on colorectal carcinoma resections. Hum Pathol. 2011;42:36–40.CrossRefPubMed Haugland HK, Casati B, Dørum LM, et al. Template reporting matters: a nationwide study on histopathology reporting on colorectal carcinoma resections. Hum Pathol. 2011;42:36–40.CrossRefPubMed
24.
go back to reference Huang X, Gao P, Song Y, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the Cell Search System in colorectal cancer. BMC Cancer. 2015;30;15:202.CrossRef Huang X, Gao P, Song Y, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the Cell Search System in colorectal cancer. BMC Cancer. 2015;30;15:202.CrossRef
25.
go back to reference Allen-Mersh TG, McCullough TK, Patel H, et al. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg. 2007;94:96–105.CrossRefPubMed Allen-Mersh TG, McCullough TK, Patel H, et al. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg. 2007;94:96–105.CrossRefPubMed
26.
go back to reference Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. Arch Pathol Lab Med. 2000;124(7):979–94.PubMed Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. Arch Pathol Lab Med. 2000;124(7):979–94.PubMed
27.
go back to reference Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97:219–25.CrossRefPubMed Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst. 2005;97:219–25.CrossRefPubMed
28.
go back to reference Baxter NN. Is lymph node count an ideal quality indicator for cancer care? J Surg Oncol. 2009;99:265–268.CrossRefPubMed Baxter NN. Is lymph node count an ideal quality indicator for cancer care? J Surg Oncol. 2009;99:265–268.CrossRefPubMed
29.
go back to reference Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295–308.CrossRefPubMed Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295–308.CrossRefPubMed
30.
go back to reference Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pNo. Cancer. 2001;92(2):452.CrossRefPubMed Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pNo. Cancer. 2001;92(2):452.CrossRefPubMed
31.
go back to reference Fleshman J. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer? Ann Surg. 2009;249(4):564.CrossRefPubMed Fleshman J. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer? Ann Surg. 2009;249(4):564.CrossRefPubMed
32.
go back to reference Søreide K, Nedrebø BS, Søreide JA, et al. Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. World J Surg. 2009;33:2695–703.CrossRefPubMed Søreide K, Nedrebø BS, Søreide JA, et al. Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. World J Surg. 2009;33:2695–703.CrossRefPubMed
33.
go back to reference Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2011;30:60–70.CrossRefPubMed Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2011;30:60–70.CrossRefPubMed
34.
go back to reference Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–29.CrossRefPubMed Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–29.CrossRefPubMed
35.
go back to reference André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol. 2009;27:3109–16.CrossRefPubMed André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol. 2009;27:3109–16.CrossRefPubMed
36.
go back to reference O’Connor ES, Greenblatt DY, LoConte NK. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–88.CrossRefPubMedPubMedCentral O’Connor ES, Greenblatt DY, LoConte NK. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–88.CrossRefPubMedPubMedCentral
37.
go back to reference Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev. 2013;39:622–31.CrossRefPubMed Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev. 2013;39:622–31.CrossRefPubMed
38.
go back to reference Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–29.CrossRefPubMed Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–29.CrossRefPubMed
39.
go back to reference Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008;19:935–38.CrossRefPubMed Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008;19:935–38.CrossRefPubMed
40.
go back to reference Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138:1714–26.CrossRefPubMed Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138:1714–26.CrossRefPubMed
41.
go back to reference Peach G, Kim C, Zacharakis E, et al. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010; 102:1327–34.CrossRefPubMedPubMedCentral Peach G, Kim C, Zacharakis E, et al. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010; 102:1327–34.CrossRefPubMedPubMedCentral
42.
go back to reference Sastre J, Vidaurreta M, Gómez A, et al. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2013;12:280–86.CrossRefPubMed Sastre J, Vidaurreta M, Gómez A, et al. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2013;12:280–86.CrossRefPubMed
43.
go back to reference Brudvik KW, Seeberg LT, Hugenschmidt H, et al. Detection of circulating tumor cells at surgery and at follow-up assessment to predict survival after two-stage liver resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(12):4029–37.CrossRefPubMed Brudvik KW, Seeberg LT, Hugenschmidt H, et al. Detection of circulating tumor cells at surgery and at follow-up assessment to predict survival after two-stage liver resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(12):4029–37.CrossRefPubMed
44.
go back to reference Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–31.CrossRefPubMed Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–31.CrossRefPubMed
45.
go back to reference Gazzaniga P, Raimondi C, Gradilone A, et al. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? J Cancer Res Clin Oncol. 2013;139:1411–16.CrossRefPubMed Gazzaniga P, Raimondi C, Gradilone A, et al. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? J Cancer Res Clin Oncol. 2013;139:1411–16.CrossRefPubMed
46.
go back to reference Katsuno H, Zacharakis E, Aziz O, et al. Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. Ann Surg Oncol. 2008;5:3083–91.CrossRef Katsuno H, Zacharakis E, Aziz O, et al. Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. Ann Surg Oncol. 2008;5:3083–91.CrossRef
47.
go back to reference Giessen C, Fischer von Weikersthal L, Laubender RP, et al. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. Br J Cancer. 2013;109:1428–1436.CrossRefPubMedPubMedCentral Giessen C, Fischer von Weikersthal L, Laubender RP, et al. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. Br J Cancer. 2013;109:1428–1436.CrossRefPubMedPubMedCentral
48.
go back to reference Van Dalum G, Stam G-J, Scholten L, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46(3):1361–8.PubMed Van Dalum G, Stam G-J, Scholten L, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46(3):1361–8.PubMed
49.
go back to reference McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol. 2009;5:1083–98.CrossRefPubMed McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol. 2009;5:1083–98.CrossRefPubMed
50.
go back to reference Borgen E, Naume B, Nesland JM, et al. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry. 2001;46:215–21.CrossRefPubMed Borgen E, Naume B, Nesland JM, et al. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry. 2001;46:215–21.CrossRefPubMed
Metadata
Title
Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
Authors
Lars Thomas Seeberg, MD
Cathrine Brunborg, MSc
Anne Waage, MD, PhD
Harald Hugenschmidt, MD
Anne Renolen, MSc
Ingunn Stav, MSc
Bjørn A. Bjørnbeth, MD, PhD
Elin Borgen, MD, PhD
Bjørn Naume, MD, PhD
Kristoffer W. Brudvik, MD, PhD
Gro Wiedswang, MD, PhD
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-5818-2

Other articles of this Issue 8/2017

Annals of Surgical Oncology 8/2017 Go to the issue